112 related articles for article (PubMed ID: 32161011)
41. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
42. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
43. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
Yang F; Lv LZ; Cai QC; Jiang Y
World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
[TBL] [Abstract][Full Text] [Related]
44. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells.
Cai K; Wan Y; Sun G; Shi L; Bao X; Wang Z
Oncol Rep; 2012 Dec; 28(6):2101-6. PubMed ID: 22972404
[TBL] [Abstract][Full Text] [Related]
45. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
46. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
48. Long non-coding RNA PVT1 indicates a poor prognosis of glioma and promotes cell proliferation and invasion via target EZH2.
Yang A; Wang H; Yang X
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046366
[TBL] [Abstract][Full Text] [Related]
49. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
50. Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.
Chen Y; Xie H; Zou Y; Lai X; Ma L; Liu Y; Li J
Mol Biosyst; 2017 Jul; 13(8):1597-1607. PubMed ID: 28671703
[TBL] [Abstract][Full Text] [Related]
51. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
52. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract][Full Text] [Related]
54. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
[TBL] [Abstract][Full Text] [Related]
55. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
[TBL] [Abstract][Full Text] [Related]
56. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach.
Dai H; Li R; Wheeler T; Ozen M; Ittmann M; Anderson M; Wang Y; Rowley D; Younes M; Ayala GE
Hum Pathol; 2007 Feb; 38(2):299-307. PubMed ID: 17097719
[TBL] [Abstract][Full Text] [Related]
57. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer.
Okui N; Kamata Y; Sagawa Y; Kuhara A; Hayashi K; Uwagawa T; Homma S; Yanaga K
Pancreatology; 2019 Jan; 19(1):88-96. PubMed ID: 30416041
[TBL] [Abstract][Full Text] [Related]
58. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
60. [Effects of enhancer of zeste homolog (EZH2) downregulation on the proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanisms].
LIANG BJ; LI XP; LU J; LIN SX; LIU X; LI G; ZHANG B; WANG L; LUO HN; WAN RQ; TIAN WD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 47(4):298-304. PubMed ID: 22800347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
